Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE phase 2 trial of nivolumab + ipilimumab in molecularly selected metastatic castration-resistant prostate cancer
NL-OMON49591Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in metastatic castration-resistant prostate cancer (mCRPC) and prostate adenocarcinoma (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Disease control rate lasting more than 6 months. Started Jan 2021; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate adenocarcinoma
Beyond the preview
Go deeper on NL-OMON49591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49591.